EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Nanomedicine in Lung Cancer Immunotherapy

Mohammad Doroudian, Saba Zanganeh, Elham Abbasgholinejad, Seamas C Donnelly

Frontiers in Bioengineering and Biotechnology · 2023-03-17 · 11

DOI: 10.3389/fbioe.2023.1144653 ↗

At a glance

Übersichtsarbeit in Frontiers in Bioengineering and Biotechnology, published online on 2023-03-17. Written by Mohammad Doroudian and 3 co-authors. Institution: School of Medicine, Trinity College, Trinity Biomedical Sciences Institute, Dublin, Ireland. Cited 54 times so far (Crossref); 90 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Lung cancer is the major cause of cancer death worldwide. Cancer immunotherapy has been introduced as a promising and effective treatment that can improve the immune system’s ability to eliminate cancer cells and help establish immunological memory. Nanoparticles can contribute to the rapidly evolving field of immunotherapy by simultaneously delivering a variety of immunological agents to the target site and tumor microenvironment. Nano drug delivery systems can precisely target biological pathways and be implemented to reprogram or regulate immune responses. Numerous investigations have been conducted to employ different types of nanoparticles for immunotherapy of lung cancer. Nano-based immunotherapy adds a strong tool to the diverse collection of cancer therapies. This review briefly summarizes the remarkable potential opportunities for nanoparticles in lung cancer immunotherapy and its challenges.

Subjects

Author keywords

drug deliveryimmunotherapylung cancernanocarriersnanomedicine

Authors and institutions

  • School of Medicine, Trinity College, Trinity Biomedical Sciences Institute, Dublin, Ireland.
  • Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
  • Department of Clinical Medicine, Trinity College Dublin, Tallaght University Hospital, Dublin, Ireland.

Cite

APA

Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023). Nanomedicine in Lung Cancer Immunotherapy. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1144653

Vancouver

Doroudian M, Zanganeh S, Abbasgholinejad E, Donnelly SC. Nanomedicine in Lung Cancer Immunotherapy. Frontiers in Bioengineering and Biotechnology. 2023;11. doi:10.3389/fbioe.2023.1144653

BibTeX
@article{Doroudian2023,
  author = {Doroudian, Mohammad and Zanganeh, Saba and Abbasgholinejad, Elham and Donnelly, Seamas C},
  title = {Nanomedicine in Lung Cancer Immunotherapy},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2023},
  volume = {11},
  doi = {10.3389/fbioe.2023.1144653}
}
Start for free →